CLL Treatment Evolution

CE / CME

Evolving CLL Treatment Recommendations

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: October 06, 2022

Expiration: October 05, 2023

Nichole Fisher
Nichole Fisher, RN, BSN
Nicole Lamanna
Nicole Lamanna, MD
Anthony J. Perissinotti
Anthony J. Perissinotti, PharmD, BCOP

Activity

Progress
1
Course Completed

References

  1. Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129:2612-2615.
  2. Williams AM, Baran AM, Casulo C, et al. Ibrutinib dose adherence and therapeutic efficacy in non-Hodgkin lymphoma: a single-center experience. Clin Lymphoma Myeloma Leuk. 2019;19:41-47.
  3. Topping RP, Rosenthal K, Awan FT, et al. Evolving treatment patterns in chronic lymphocytic leukemia among experts and community practitioners: analysis of an online decision support tool. Blood. 2020;136(suppl 1):41-42.
  4. Venetoclax prescribing information. North Chicago, IL: AbbVie Inc., and South San Francisco, CA: Genentech, Inc; 2021.
  5. Obinutuzumab prescribing information. South San Francisco, CA: Genentech, Inc; 2022.
  6. Acalabrutinib prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.
  7. Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196:947-953.
  8. Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36:1171-1175.
  9. Al-Sawaf O, Zhang C, Robrecht S, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. Presented at: European Hematology Association Congress; June 9-17, 2021. Abstract S146.
  10. Tausch E, Schneider C, Robrecht S, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135:2402-2412.
  11. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441-3452.
  12. Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: European Hematology Association Congress; June 9-17, 2021. Abstract LB1900.
  13. Patel H, Wahlstrom SK, DerSarkissian M, et al. Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL) treated with acalabrutinib, ibrutinib, or venetoclax. Blood. 2021;138(suppl 1):2999.